Roder J D, Stein H J, Siewert J R
Department of Surgery, Technische Universität München, Klinikum rechts der Isar, Germany.
Am J Surg. 1996 Jan;171(1):170-4; discussion 174-5. doi: 10.1016/S0002-9610(99)80094-4.
The prognosis of patients with carcinoma of the periampullary region infiltrating the portal vein is dismal.
We assessed the morbidity, mortality, and prognosis of pancreatoduodenectomy in 31 patients in whom a tangential excision (n = 9) or a segmental resection (n = 22) of the portal vein or superior mesenteric vein was performed in an attempt to achieve complete tumor removal.
There was no postoperative mortality. Tumor infiltration of the resected vein could be documented histopathologically in 19 of the 31 (61.3%) patients. All patients with pancreatic or bile duct carcinoma (n = 29) died within 16 months of the resection (median survival 8 months). In contrast, 2 patients with cystadenocarcinoma and acinous cell carcinoma are alive with no evidence of recurrence at 23 and 54 months, respectively.
Portal vein resection does not prolong survival in patients undergoing partial pancreatoduodenectomy for carcinoma of the pancreas or distal bile duct. Only the occasional patient with a rare tumor at this region may benefit from this approach.
壶腹周围癌侵犯门静脉的患者预后很差。
我们评估了31例行胰十二指肠切除术患者的发病率、死亡率及预后情况,这些患者中行门静脉或肠系膜上静脉的切线切除(n = 9)或节段性切除(n = 22)以试图完整切除肿瘤。
无术后死亡病例。31例患者中有19例(61.3%)经组织病理学证实切除静脉有肿瘤浸润。所有胰腺癌或胆管癌患者(n = 29)均在切除术后16个月内死亡(中位生存期8个月)。相比之下,2例囊腺癌和腺泡细胞癌患者分别在术后23个月和54个月存活,无复发迹象。
门静脉切除并不能延长因胰腺癌或远端胆管癌接受部分胰十二指肠切除术患者的生存期。只有该区域偶尔发生罕见肿瘤的患者可能从这种手术方式中获益。